Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Resource centre
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

19 November 2024

Pharma still ‘falling short’ in providing access to low- and middle-income countries, analysis finds

In a recent article for STAT, Ed Silverman highlights the Access to Medicine Foundation's latest report, which assesses 20 of the world's largest pharmaceutical companies in relation to their efforts to expand access to medicine.

Direct links

Read the full article

The article emphasises that although pharmaceutical companies have made some progress in expanding access to essential healthcare products in low- and middle-income countries (LMICs), their overall efforts remain limited.  

Specifically, despite companies tailoring their business models to focus on low –income countries, progress has slowed in reaching licensing deals that are designed to make lower-cost generic drugs available in LMICs. Additionally, only a small number of companies have engaged in technology transfer agreements, and most clinical trials continue to be conducted outside of LMICs, despite these countries being home to the majority of the global population. 

The article also highlights that GSK and Novartis ranked at the top of the three areas measured by the Foundation for the report, including Governance of Access, Research & Development and Product Delivery. However, overall, there has been “uneven progress” among companies for implementation. 

“Since we began measuring these companies, we expected the pace of progress would pick up, but it’s falling short — and not a little bit short, but a lot short,” the article quotes Jayasree K. Iyer, CEO of the Foundation. “The big concern is how do we keep momentum going if, in fact, it’s dropping down?” 

Read now

2024 Access to Medicine Index

Read more

Divya Verma

Head of Communications

dverma@accesstomedicinefoundation.org

Get in touch

Media

Read more about our coverage in global media
Media

Op-ed: How equitable access to medicines can drive sustainable returns for investors

19 November 2024
Media

Corporate efforts to expand access to medicine stumble

19 November 2024
Media

Global drugmakers fall behind in efforts to make medicines available in poorer countries

19 November 2024

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved